Takeda Pharmaceutical (TAK) Change in Receivables (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Change in Receivables of -$445.3 million for Q2 2026, down 233.99% year-over-year from $332.3 million in Q2 2025, and up 28.39% quarter-over-quarter from -$621.8 million in Q1 2026.
Takeda Pharmaceutical (TAK) Change in Receivables (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Change in Receivables history runs 9 years deep, the most recent figure standing at -$445.3 million for Q2 2026.
- In Q2 2026, Change in Receivables fell 233.99% year-over-year to -$445.3 million; the TTM figure through Jun 2026 stood at -$1.2 billion (down 567.65% YoY), while the FY2026 annual figure was -$466.1 million, down 20.43% from the prior year.
- Change in Receivables for Q2 2026 stood at -$445.3 million, up from -$621.8 million in the prior quarter.
- The five-year high for Change in Receivables was $516.1 million in Q1 2023, with the low at -$659.4 million in Q2 2023.
- The 5-year median for Change in Receivables is $8.4 million (2025), against an average of -$14.2 million.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables jumped 208.35% in 2025, then plunged 584.76% in 2026.
- Takeda Pharmaceutical's Change in Receivables stood at $90.4 million in 2022, then rose by 6.93% to $96.7 million in 2023, then dropped by 13.75% to $83.4 million in 2024, then slumped by 185.24% to -$71.1 million in 2025, then plunged by 526.59% to -$445.3 million in 2026.
- Business Quant data shows TAK's Change in Receivables at -$445.3 million in Q2 2026, -$621.8 million in Q1 2026, and -$71.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 48.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -445.26 Mn |
| Jun 30, 2026 | -445.26 Mn |
| Mar 31, 2026 | -621.82 Mn |
| Mar 31, 2026 | -621.82 Mn |
| Dec 31, 2025 | -71.06 Mn |
| Dec 31, 2025 | -71.06 Mn |
| Sep 30, 2025 | -66.49 Mn |
| Sep 30, 2025 | -66.49 Mn |
| Jun 30, 2025 | 332.31 Mn |
| Jun 30, 2025 | 332.31 Mn |
| Mar 31, 2025 | -90.81 Mn |
| Mar 31, 2025 | -90.81 Mn |
| Dec 31, 2024 | 83.37 Mn |
| Dec 31, 2024 | 83.37 Mn |
| Sep 30, 2024 | -67.28 Mn |
| Sep 30, 2024 | -67.28 Mn |
| Jun 30, 2024 | -306.70 Mn |
| Jun 30, 2024 | -306.70 Mn |
| Mar 31, 2024 | 498.64 Mn |
| Mar 31, 2024 | 498.64 Mn |